Triple-negative breast cancer (TNBC), accounting for approximately 15%–20% of all BC cases, is defined as lacking the expression of ER, PR, and HER2 (Schmadeka et al., 2014). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.